MarketMoodz
Midday movers: AMD gains on Bernstein lift; Abbott slides
AMD surged more than 7% after Bernstein lifted its price target to $265 from $235, signaling renewed enthusiasm for AI hardware. Abbott Laboratories slid nearly 7% on weak Q2 guidance, while Schwab fell about 5% after revenue missed expectations; AI-related names and equipment makers topped the movers list for the session.
Key Takeaways
- AMD up >7% after Bernstein lifts price target to $265 (from $235), on pace for a 12th straight winning session
- Abbott down ~7% as Q2 adj EPS guidance comes in at $1.25-$1.31 vs $1.36 consensus; full-year adj EPS guided to $5.38-$5.58 vs $5.60
- Aehr Test Systems up ~11% on a $41M production order from a leading hyperscale AI customer
- On Semiconductor up ~9% as Bank of America lifts PT to $85 and upgrades to Buy
- Charles Schwab down ~5% after Q1 revenue of $6.48B misses consensus; launches direct bitcoin trading as competition intensifies
People Involved
- No specific individuals mentioned
Entities Involved
- Advanced Micro Devices, Inc. (AMD)Semiconductor company
- Abbott LaboratoriesMedical devices and diagnostics company
- Aehr Test SystemsSemiconductor test equipment supplier
- On Semiconductor Corp. (ON)Semiconductor supplier
- Lumentum Holdings Inc.Optical and photonics products maker
- Coherent Corp.Laser and photonics equipment maker
- PepsiCo, Inc.Food and beverage company
- Taiwan Semiconductor Manufacturing Co. (TSMC)Leading semiconductor foundry
- PPG Industries, Inc.Coatings and specialty materials
- J.B. Hunt Transport Services, Inc.Logistics and trucking
- Old Dominion Freight Line, Inc.Truckload carrier
- Charles Schwab Corp.Brokerage and financial services firm
- Flutter Entertainment plcOnline gambling and gaming company
- U.S. BancorpBanking and financial services
- SL Green Realty Corp.Real estate investment trust
MarketMoodz Analysis
AMD's more-than-7% rally underscores the ongoing AI hardware cycle’ s impact on equities as upgrade catalysts flow through the semiconductor space. Bernstein's price-target lift adds an external validation signal for investors chasing GPU-driven demand, contributing to a broader rotation into AI infrastructure names.
Abbott's weak Q2 guidance highlights how deal dynamics and margin pressures can override a solid top line. The Exact Sciences tie-up appears to be a headwind for near-term profitability, illustrating how M&A and collaboration bets can shift consensus expectations even in otherwise stable health-care franchises. For investors, the takeaway is to separate headline beat-and-raise nerves from the longer-term AI and diagnostics growth trajectory.
The session's breadth—ranging from AI hardware suppliers to consumer staples and banks—illustrates a market grappling with how much risk to price into AI exposure, economics, and policy shifts around crypto services. Watch for updates on AI capex signals from major equipment players, the trajectory of semiconductor demand, and any revisions to earnings guidance across sectors. Note that one item, Voyager Technologies, referenced in some reports, is unverified and should be treated with caution.
Source: Original Article